T-cell costimulation–biology, therapeutic potential, and challenges.
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The immune system has the remarkable ability to defend against diverse microbial pathogens and yet not to respond to self. T cells are key mediators of the immune response, and their activation is tightly regulated to prevent autoreactivity. The processes of T-cell activation and self-tolerance are therefore potential targets for manipulation by drugs — hence, the recent phase 1 trial of a “superagonistic” monoclonal anti-CD28 antibody that was conducted in Britain on behalf of the German firm TeGenero, with the unexpected and devastating results described by Suntharalingam et al. in this issue of the Journal (pages 1018–1028).T-cell activation requires . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“According to the currently accepted model of T cell activation, two signals are required to fully activate resting naïve T lymphocytes.”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [2]
Citations
Cites
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Self-citationCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature Reviews Immunology · doi:10.1038/nri1032 · Cited by 1,323
Self-citationCTLA4Ig: Bridging the Basic Immunology with Clinical Application
Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.001 · Cited by 276
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
CD28 superagonists: Mode of action and therapeutic potential
Hünig, T., & Dennehy, K. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.012 · Cited by 63
Drazen, J. M. (2006) · New England Journal of Medicine · doi:10.1056/nejme068175 · Cited by 13
Cited by
Items 201–203 of 203
Le, F., Jiang, Y., Chen, Y., Huang, X., Ouyang, Q., & Lü, S. (2026) · Clinical Medicine Insights Oncology · doi:10.1177/11795549261446733
An Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context
Davies, J., Brown, L., Jones, M. W., Penny, M., & Powathil, G. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0209
Avoidance of Cancer Cell Destruction by the Immune System
de la Cruz‐Merino, L., Illescas-Vacas, A., & Sánchez-Escribano, R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.01911-0
Metadata
- Authors
- Sharpe, A. H., & Abbas, A. K.
- Affiliations
- Harvard University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 973-975
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2135741926
- Cited by
- 206
- References
- 7
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 9 · 2019: 10 · 2018: 15 · 2017: 10 · 2016: 11 · 2015: 12 · 2014: 8 · 2013: 14 · 2012: 17
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- T cell costimulation, T cell activation, self-tolerance, anti-CD28 monoclonal antibody, autoimmunity, T cell biology
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigen-Presenting Cells, Humans, Immune Tolerance, Lymphocyte Activation, T-Lymphocytes, Cytokines, CD28 Antigens, Models, Animal, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.